Business
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as
About this update from Beyondspring, Inc.
[{"type":"text","content":"- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as chemotherapy), had non-inferior protection against CIN compared to pegfilgrastim (day 2 dose), while performing numerically better for reduction of febrile neutropenia and chemo dose delay, with significantly lower bone pain NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced presentation of data from the PROTECTIVE-1 Phase 3 clinical study of plinabulin for prevention of chemotherapy-induced neutropenia (CIN) at the American Society of Clinical Oncology (ASCO) Annual Meeting being held on June 4 - 8, 2021. The poster titled “Head-to-Head Comparison of Single Agent (SA) Plinabulin (Plin) versus Pegfilgrastim (Peg) for the Prevention of Chemotherapy-Induced Neutropenia (CIN) in the Phase 3 Trial PROTECTIVE-1,” was presented at 9:00 a.m. ET on June 4, 2021, at Lung Cancer Poster Session (Abstract #547) is the PROTECTIVE-1 Phase 3 data comparing plinabulin versus pegfilgrastim. Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy with results including clinically meaningful endpoints for reduction of febrile neutropenia (FN), hospitalization and bone pain. Primary endpoint of demonstrating non-inferiority of single agent plinabulin versus single agent pegfilgrastim was met: DSN (days of severe neutropenia) cycle 1, non-inferiority margin of 0.65 day criterion between plinabulin and pegfilgrastim was met.Comparable or numerically better clinical sequelae of CIN for plinabulin vs. pegfilgrastim: FNInfectionAntibioticsUseHospitalizationDocetaxelDiscontinueDocetaxelDelayPlin (n=52)0%7.69%15.4%3.84%13.5%3.85%Peg (n=53)1.89%15.1%13.2%1.89%26.4%5.66% Significant improvement in bone pain and platelet count: Less bone pain (p=0.01) and less thrombocytopenia (p","length":8450,"tagName":"div"}]